Safety and Efficacy of AMG 827 in Subjects With RA

PHASE2TerminatedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

June 3, 2010

Primary Completion Date

April 5, 2011

Study Completion Date

April 5, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

AMG 827

AMG 827 210 mg

Trial Locations (44)

1002

Research Site, Riga

1006

Research Site, Riga

1612

Research Site, Sofia

1709

Research Site, Sofia

3400

Research Site, Liepāja

3901

Research Site, Bauska

5000

Research Site, Veliko Tarnovo

5417

Research Site, Daugavpils

14050

Research Site, Mexico City

16635

Research Site, Duncansville

22010

Research Site, Tijuana

34239

Research Site, Sarasota

40504

Research Site, Lexington

44690

Research Site, Guadalajara

48910

Research Site, Lansing

49546

Research Site, Grand Rapids

58070

Research Site, Morelia

61201

Research Site, Rock Island

62704

Research Site, Springfield

78240

Research Site, San Luis Potosí City

85258

Research Site, Scottsdale

85711

Research Site, Tucson

92037

Research Site, La Jolla

92395

Research Site, Victorville

97239

Research Site, Portland

98405

Research Site, Tacoma

07728

Research Site, Freehold

R3N 0K6

Research Site, Winnipeg

A1A 5E8

Research Site, St. John's

M5T 2S8

Research Site, Toronto

H2L 1S6

Research Site, Montreal

140 59

Research Site, Prague

148 00

Research Site, Prague

06700

Research Site, Mexico City

15-351

Research Site, Bialystok

15-461

Research Site, Bialystok

20-607

Research Site, Lublin

60-356

Research Site, Poznan

87-100

Research Site, "ToruÅ"

02-118

Research Site, Warsaw

50-044

Research Site, Wroclaw

50-088

Research Site, Wroclaw

96-300

Research Site, Żyrardów

L49 5PE

Research Site, Merseyside

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY